Comparison of Pulmonary Function Decline in Steroid-Treated and Steroid-Naive Patients with Duchenne Muscular Dystrophy

被引:12
|
作者
Sawnani, Hemant [1 ,2 ]
Horn, Paul S. [2 ,3 ]
Wong, Brenda [2 ,3 ]
Darmahkasih, Andrew [4 ]
Rybalsky, Irina [2 ,3 ]
Shellenbarger, Karen C. [3 ]
Tian, Cuixia [2 ,3 ]
Rutter, Meilan M. [2 ,5 ]
Simakajornboon, Narong [1 ,2 ]
Amin, Raouf [1 ,2 ]
Gurbani, Neepa [1 ,2 ]
Pascoe, John [1 ,2 ]
Burrows, Carolyn [1 ]
Khirani, Sonia [6 ,7 ]
Amaddeo, Alessandro [6 ]
Fauroux, Brigitte [6 ]
机构
[1] Cincinnati Childrens Hosp Med Ctr, Div Pulm Med, MLC 7041,3333 Burnet Ave, Cincinnati, OH 45229 USA
[2] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA
[3] Cincinnati Childrens Hosp Med Ctr, Div Neurol, Cincinnati, OH 45229 USA
[4] Wayne State Univ, Sch Med, Detroit, MI USA
[5] Cincinnati Childrens Hosp Med Ctr, Div Endocrinol, Cincinnati, OH 45229 USA
[6] Necker Univ Hosp, Pediat Noninvas Ventilat & Sleep Unit, Paris, France
[7] ASV Sante, Gennevilliers, France
来源
JOURNAL OF PEDIATRICS | 2019年 / 210卷
关键词
RESPIRATORY-FUNCTION; PREDNISONE THERAPY; HEIGHT; TRIAL; SURVIVAL; IMPACT;
D O I
10.1016/j.jpeds.2019.02.037
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Objective To describe and compare the lung function decline in patients with Duchenne muscular dystrophy on glucocorticoid therapy in contrast with glucocorticoid-naive patients, and to define the deciles of pulmonary decline in glucocorticoid-treated patients. Study design This retrospective study examined lung function of patients with Duchenne muscular dystrophy over 6 years of age followed between 2001 and 2015 at 2 centers-glucocorticoid-treated patients in Cincinnati, Ohio, and glucocorticoid-naive patients in Paris, France. Forced vital capacity (FVC, FVC%), forced expiratory volume in 1 second, maximal inspiratory pressure, maximal expiratory pressure, and peak expiratory flow data were analyzed. Only FVC data were available for the French cohort. Results There were 170 glucocorticoid-treated patients (92%), 5 patients (2.7%) with past glucocorticoid use, and 50 French glucocorticoid-naIve patients. The peak absolute FVC was higher and was achieved at earlier ages in glucocorticoid-treated compared with glucocorticoid-naive patients (peak FVC, 2.4 +/- 0.6 L vs 1.9 +/- 0.7 L; P < .0001; ages 13.5 +/- 3.0 years vs 14.3 +/- 2.8 years; P = .03). The peak FVC% was also higher and was achieved at earlier ages in glucocorticoid-treated patients (peak FVC%, 105.1 +/- 25.1% vs 56 +/- 20.9%; P < .0001; ages 11.9 +/- 2.9 years vs 13.6 +/- 3.2 years; P = .002). Rates of decline for both groups varied with age. Maximal rates of decline were 5.0 +/- 0.26% per year (12-20 years) for glucocorticoid-treated and 5.1 +/- 0.39% per year for gluco-corticoid-naive patients (11-20 years; P = .2). Deciles of FVC% decline in glucocorticoid-treated patients show that patients experience accelerated decline at variable ages. Conclusions These data describe nonlinear rates of decline of pulmonary function in patients with Duchenne muscular dystrophy, with improved function in glucocorticoid-treated patients. FVC% deciles may be a useful tool for clinical and research use.
引用
收藏
页码:194 / +
页数:9
相关论文
共 50 条
  • [21] Steroid therapy and cardiac function in Duchenne muscular dystrophy
    Markham, LW
    Spicer, RL
    Khoury, PR
    Wong, BL
    Mathews, KD
    Cripe, LH
    PEDIATRIC CARDIOLOGY, 2005, 26 (06) : 768 - 771
  • [22] Steroid therapy and respiratory function in Duchenne muscular dystrophy
    D'Angelo, M. G.
    LoMauro, A.
    Romei, M.
    Gandossini, S.
    Brighina, E.
    Marchi, E.
    Bresolin, N.
    Aliverti, A.
    NEUROMUSCULAR DISORDERS, 2014, 24 (9-10) : 858 - 858
  • [23] Lung function monitoring in patients with duchenne muscular dystrophy on steroid therapy
    Darlene L Machado
    Elaine C Silva
    Maria B D Resende
    Celso R F Carvalho
    Edmar Zanoteli
    Umbertina C Reed
    BMC Research Notes, 5 (1)
  • [24] Does steroid therapy influence pulmonary function decline in adults with Duchenne muscular dystrophy after loss of ambulation?
    Pietrusz, A.
    Astin, R.
    Ramdharry, G.
    Quinlivan, R.
    Desikan, M.
    NEUROMUSCULAR DISORDERS, 2020, 30 : S132 - S132
  • [25] Comparison of the effect of three steroid regimens on cardiac function in Duchenne muscular dystrophy
    Sanchez, M. Josefina
    Scott, William
    Pessana, Franco
    Castro, Diana
    Ramaciotti, Claudio
    PROGRESS IN PEDIATRIC CARDIOLOGY, 2022, 67
  • [26] Motor function measure scale, steroid therapy and patients with Duchenne muscular dystrophy
    da Silva, Elaine C.
    Machado, Darlene L.
    Resende, Maria B. D.
    Silva, Renata F.
    Zanoteli, Edmar
    Reed, Umbertina C.
    ARQUIVOS DE NEURO-PSIQUIATRIA, 2012, 70 (03) : 191 - 195
  • [27] Delays in pulmonary decline in eteplirsen-treated patients with Duchenne muscular dystrophy
    Iff, Joel
    Gerrits, Charles
    Zhong, Yi
    Tuttle, Edward
    Birk, Erica
    Zheng, Yeya
    Paul, Xander
    Henricson, Erik K.
    McDonald, Craig M.
    MUSCLE & NERVE, 2022, 66 (03) : 262 - 269
  • [28] NEURODEVELOPMENTAL CONCERNS AND PSYCHOSOCIAL ADJUSTMENTS IN 193 YOUNG STEROID-NAIVE BOYS WITH DUCHENNE MUSCULAR DYSTROPHY FROM THE FOR-DMD TRIAL.
    Thangarajh, Mathula
    Hendriksen, Jos
    McDermott, Michael
    Martens, Bill
    Hart, Kim
    Griggs, Robert
    MUSCLE & NERVE, 2018, 58 : S15 - S15
  • [29] The Natural History of Cardiac and Pulmonary Function Decline in Patients With Duchenne Muscular Dystrophy
    Roberto, Rolando
    Fritz, Anto
    Hagar, Yolanda
    Boice, Braden
    Skalsky, Andrew
    Hwang, Hosun
    Beckett, Laurel
    McDonald, Craig
    Gupta, Munish
    SPINE, 2011, 36 (15) : E1009 - E1017
  • [30] Daily or alternative, that is the question: steroid therapy for Duchenne muscular dystrophy patients
    Liang, Wen-Chen
    Nishino, Ichizo
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2013, 84 (06): : 591 - 591